Navigation Links
Merck in the Dock Due To Vioxx

The Vioxx case takes a bad turn when the Texas jury awarded $32 million for the family of a 71-year-old man who had died after consuming the painkiller Vioxx. // But this will be greatly reduced by state law. The legal experts say that the verdict is a weak case against Vioxx maker Merck & Co. Inc.

The jury awarded Leonel Garza's family $7 million in compensatory damages for mental anguish and personal loss and $25 million in punitive damages, but the latter will be cut to no more than $750,000 because of a cap imposed by Texas law. Merck immediately said it would appeal the decision. It withdrew the $2.5 billion-a-year drug after it found that the use of Vioxx for more than 18 months doubled the risk of stroke and heart attack. Attorneys for Garza's family said that Vioxx caused blood clots that led to a fatal heart attack. They said Merck lied when it said only long-term use of Vioxx presented health dangers and accused the company of keeping the drug on the market long after learning of its risks because the New Jersey-based company needed the sales.

This led to the discovery that short-term use of Vioxx as a causative of heart attacks. Merck lawyers blamed Garza's death on heart disease that had plagued him since 1978. Merck attorney Richard Josephson said medical records indicate he may have taken Vioxx for only a week and stopped the medicine nearly three weeks before his death which shows that Vioxx was not involved in any way in Leonel Garza's death. But Kenneth Frazier, senior vice president and general counsel, told a conference call after the verdict that the company would fight each case and settle none.

Merck last year spent $285 million on legal fees related to Vioxx, and said its reserve fund for future litigation stood at $685 million at the end of 2005. Wall Street is watching the Vioxx trials closely for clues about how much the Vioxx issue ultimately will cost Merck. Shares of Merck closed down 26 cents at $34.74
'"/>




Page: 1 2

Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
4. Judgment In Favor Of Merck For Vioxx Drug
5. Merck, ICMR to conduct joint trials on cervical cancer vaccine
6. Merck Says Januvia Effective In Type 2 Diabetes
7. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
8. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
9. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
10. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
11. Ranbaxy in Fray to Buy Mercks Generic Drugs Unit
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Merck the Dock Due Vioxx

(Date:10/10/2008)...ILLE, PA The American Nurses Credentialing Center...MC) as a Magnet hospital. The news came via a conf... staff who broke out with cheers and applause., G...spitals and only 294 hospitals in the United Stat...00 hospitals are eligible for this recognition., ...
(Date:10/10/2008)...suggests poor self-care partly to blame , ... of Medicare beneficiaries who have diabetes, bein...e, according to a new study. , Publishing in ...nal Medicine , researchers from the University of ...average age of 75.6 years) who had diabetes and we...
(Date:10/10/2008)... Honoring excellence in the imp...he Healthcare Information and Management Systems S...8 Davies Awards in the Organizational, Ambulatory ... Chicago, IL (PRWEB) October...tion of electronic health records (EHRs), the Hea...
(Date:10/10/2008)...W YORK, Oct. 10 /PRNewswire/ -- The Johns Hopkins ... multimedia educational program,"Optimizing Adjuv...reatment,Selection," to present recent key researc...atment., In recent years, advancements in the tre...ic and biologic treatment combinations that are,in...
Breaking Medicine News(10 mins):Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2
... girls are six times more likely to have a Body Ma...ears ago and //ten-year-olds are five times more l...l issue of Acta Paediactrica. Swedish researchers... a thousand children over two decades discovered t...
... of diabetes among indigenous people is not due to...ublished study// . The study was authored by Dr Y...es School of Health Research along with two resear... that the high rates of diabetes among indigenous ...
... and Drug Administration (FDA) is alerting consume...olives that may be contaminated with a deadly bact...se botulism, a potentially fatal illness. The oliv...i S.r.l, of Bari, Italy and are being recalled by ...
...an’s daily calcium intake is an effective way of i...than average risk of osteoporosis, according to a ...ity School of Medicine, Barcelona, Spain, looked a...tate cancer. 72 per cent were receiving androgen-d...
Other Medicine News:Health News:20-year Study Shows Significant Rise in Childhood Obesity, Especially Among Girls 2Health News:FDA Urgently Warns Consumers About Health Risks of Potentially Contaminated Olives 2Health News:Measuring Calcium Intake Help to Identify Osteoporosis in Prostate Cancer Patient 2
(Date:10/8/2008)...d Scientists Expand Testing Using Cellular ...ND, Maine, Oct. 8 /- Wild Blueberry a...e of results from a new study,showing Wild Blueber...fruits like apples, bananas, red grapes and strawb...oxidant Activity (CAA) assay. New research,publish...
(Date:10/8/2008)...ws clinical improvement in patients with pulmonary...reatment options have limited benefit for this deb...blood vessel disease, -- Imatinib mesylate, ava... cancers, known to inhibit protein associated with...of imatinib mesylate in PAH in 2009 EAST HAN...
(Date:10/7/2008)...RNewswire/ -- The Texas Cardiac Arrhythmia,Institu...elected as one of,only a few sites in the nation t...r a new device to treat persistent atrial fibrilla...nd research center specializing in heart,rhythm di...cal Center and,Texas Cardiovascular Consultants., ...
(Date:10/7/2008)...ewswire-FirstCall/ -- CEL-SCI Corporation,(NYSE: ...aterial Transfer,Agreement (MTA) with the National...the laboratory of Dr. Francesco M. Marincola, M.D.... the tumor microenvironment,caused by CEL-SCI,s ca...,the Infectious Disease and Immunogentics Section,...
Breaking Medicine Technology:Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Omega 3 intake during last months of pregnancy boosts an infant 26 23146 3Bs cognitive and motor development 16355 1Omega 3 intake during last months of pregnancy boosts an infant 26 23146 3Bs cognitive and motor development 16355 2International symposium explores fire suppression economics 2828 1International symposium explores fire suppression economics 2828 2Global Med Technologies 28R 29 Inc and Cerner Announce Strategic Alliance 16349 1Global Med Technologies 28R 29 Inc and Cerner Announce Strategic Alliance 16349 2Global Med Technologies 28R 29 Inc and Cerner Announce Strategic Alliance 16349 3Miami Hospital Market Sees Shift in Ownership of Two Area Facilities 16345 1Miami Hospital Market Sees Shift in Ownership of Two Area Facilities 16345 2
...pound Could Be Utilized as an Adjuvant and Play Ke...COTTSDALE, Ariz., March 20, 2007 /PRNewswire-First...ubsidiary of IR,BioSciences Holdings, Inc. , annou...s Substance P analog, Homspera, suggests that the,...gent or vaccine,adjuvant. Studies performed in ani...
...lition for a Stronger FDA says drug review program...ewswire-USNewswire/ -- A new,estimate by the Alzhe...on Americans are living with Alzheimer,s disease -...a number that could more,than triple in the coming...oped for the debilitating illness. , The new numbe...
Other Medicine Technology:ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 2ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 3ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 4Alzheimer's Growth Shows Need for Increased FDA Funding 2Alzheimer's Growth Shows Need for Increased FDA Funding 3
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base.
Certified by an independent laboratory to meet Class 100 specifications of Federal Standard 209E. Ergonomic seat guarantees worker confort, reduces fatique and back injuries. Clean vinyl meets Class
Inquire
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in.
Medicine Products: